Eisai Pharma launches new anti-epilepsy drug in India
Eisai Pharmaceuticals' anti-epilepsy drug Fycompa will be available in three strengths of 2 mg, 4 mg and 6 mg, with per day cost to patients at Rs35, Rs55 and Rs70 for each strength
Mumbai: Eisai Pharmaceuticals India Pvt. Ltd on Tuesday launched anti-epilepsy drug Fycompa in India.
The once-a-day perampanel tablet—parempanel is the chemical name of the drug, which will be sold under the brand name Fycompa—will be available in three strengths 2 mg, 4 mg and 6 mg with per day cost to patients being Rs35, Rs55 and Rs70 for each strength, respectively, managing director Sanjit Singh Lamba said at a press conference.
The cost of Fycompa in India is much lower than $15-16 per day in the US, he said. The drug is already approved in more than 55 countries in the world.
Eisai Pharmaceuticals India is a subsidiary of Japan’s Eisai Co. Ltd.
Nearly 12 million Indians suffer from epilepsy and 95% of them do not receive adequate treatment, Lamba said.
The market size for epilepsy drugs in India is Rs2,900 crore and the company aims Fycompa sales to be Rs20 crore over the next three years.
Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!